import { Placeholder } from "@angular/compiler/src/i18n/i18n_ast";

const tsv_str = `https://docs.google.com/document/d/14S-BF8kDm1xhNlZvz5jgBiaciAB91o_QyiPbqj5zPAs/edit?usp=sharing	Name	NameCh	Affiliations	Headshot link	ImgFileName	Description link	Description	Networking(lunch or breakfast)	Links	Email	Parking
Opeining remarks	Pei-Jung Wu	吳佩容	Scientist, Analytical Development, Intellia Therapeutics, Inc.	Pei-Jung Headshot	Pei-Jung Wu.jpg		<p>Pei-Jung is an Analytical Development Scientist at Intellia Therapeutics, specializing in the characterization of viral and CRISPR-based gene therapies. With a focus on designing robust analytical methods, she ensures accurate assessment of product quality and compliance with regulatory guidelines. Prior to Intellia, her contributions at Rubius Therapeutics included the development of novel analytical strategies for the characterization of allogenic Red-Cell Therapeutics™ (RCTs) and the LVV platform. In her previous role at Eurofins PSS, Pei-Jung successfully implemented the development and qualification of impurity and potency assays to support autologous CAR-T development. Alongside her technical proficiency, Pei-Jung has also demonstrated leadership qualities by providing guidance and mentorship to junior scientists. </p>		https://www.linkedin.com/in/pei-jung-wu-94ba1a159/	peijung.wutw@gmail.com	3WNZ39
Opeining remarks	Ming-Ju Tsai	蔡明儒	Senior Scientist, Computational Biology, Takeda	Ming-Ju headshot	Ming-Ju_Tsai.jpg		<p>Ming-Ju Tsai is currently a Senior Scientist within the Preclinical and Translational Science Department of the Computational Biology function at Takeda Pharmaceuticals. He focuses on the application of ML/AI methods with omics data to support pre-clinical and translational pipelines. Before joining Takeda, Ming-Ju served as a Senior Scientist on the Computational Biology team at Kronos Bio, concentrating on drug discovery. In this role, he leveraged multi-omics data to construct transcriptional regulatory networks and identify targets in the field of oncology. Prior to his work in industry, Ming-Ju was a Postdoctoral Research Fellow at Harvard Medical School. </p>		https://www.linkedin.com/in/mingju-tsai/	mingjutsai49@gmail.com	1SKY95
Keynote	Laura Sepp-Lorenzino		Chief Scientific Officer, Intellia Therapeutics	Laura headshot	laura-sepp.jpg	Laura shortbio	<p>Dr. Laura Sepp-Lorenzino is Executive Vice President, Chief Scientific Officer at Intellia Therapeutics, a company developing curative genome editing treatments to positively transform the lives of people with genetic diseases. She oversees all drug research across in vivo and engineered cell therapy areas at Intellia. Previously, she was VP, Head Nucleic Acid Therapies at Vertex Pharmaceuticals and before that, VP, Entrepreneur-in-Residence at Alnylam, a leader in the development of RNAi Therapeutics. At Alnylam, Laura was responsible for the Hepatic Infectious Disease Strategic Therapeutic Area, championed Extra Hepatic siRNA Delivery internally, and via a number of collaborations, was active in licensing and partnering. Before joining Alnylam, she spent 14 years at Merck & Co., having most recently served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, Laura was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of preclinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to her work with RNAi, Laura led the Cancer Research Department at Merck West Point, where she managed oncology drug discovery and development. She began her career in academia, as an Assistant Lab Member and Assistant Attending Molecular Biologist at Memorial Sloan-Kettering Cancer Center. Laura received her Professional Degree in Biochemistry from the University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York University.</p>		https://www.linkedin.com/in/laurasepplorenzino/
Keynote	Samir Mitragotri		Core Faculty, Wyss Institute at Harvard University	Samir headshot	Samir-Mitragotri-Listing-Image.jpg	samir shortbio	<p>Professor Mitragotri's research is focused on drug delivery. His research has advanced fundamental understanding of biological barriers and has led to the development of new materials as well as technologies for the treatment of various ailments including diabetes, cancer, skin diseases, multiple sclerosis, and infections, among others. Many of his inventions have advanced to clinical technologies. His research has led to a number of start-up companies. At the same time, the fundamental knowledge developed through his research has advanced the understanding of the biology of barriers in the human body. Prof. Mitragotri has pioneered novel technologies using ultrasound and ionic liquids to enable transdermal delivery of proteins, peptides, and siRNA. He has also developed novel technologies including ionic liquids for oral delivery of proteins such as insulin and other peptides. Prof. Mitragotri has invented systems that make use of synthetic carriers hitchhiking on natural cells such as red blood cells, macrophages, neutrophils, T cells, and NK cells for targeted delivery of drugs and cells.</p>  <p>Professor Mitragotri is the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard University. He has authored over 400 publications, is an inventor on over 225 issued/pending patents, and he has given over 500 invited lectures. He is an elected member of the National Academy of Engineering, National Academy of Medicine and National Academy of Inventors. He is also an elected fellow of AAAS, CRS, BMES, AIMBE, and AA PS. He received BS in Chemical Engineering from the Institute of Chemical Technology, India and PhD in Chemical Engineering from the Massachusetts Institute of Technology.</p>		https://wyss.harvard.edu/team/core-faculty/samir-mitragotri/
Special talk	Robert Ang		President and CEO - VOR Bio	Robert_headshot	robert-ang.jpeg	Robert short bio	<p>Robert Ang, MBBS, MBA, is President and CEO at Vor Bio, a publicly-traded company working on next-generation hematopoietic stem cell transplants. Vor uses stem cells, gene editing, and CAR-T technologies with the hope of curing liquid tumors. Vor has raised over $470M in gross proceeds from private and public financing and has translated the science into two clinical programs treating patients with acute myeloid leukemia and myelodysplastic syndrome.</p>  <p>Prior to Vor, Robert had operational experience focused on strategy and business development roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also had biotech venture capital experience at Frazier Healthcare Ventures where he invested in companies such as Incline Therapeutics (now Novartis) and Alnara Pharmaceuticals (now Eli Lilly), and strategy consulting experience at the Boston Consulting Group. His clinical practice centered around soft tissue surgery with an emphasis around solid organ transplants. He received his medical degree at the University of Western Australia and has an MBA with Honors from Columbia Business School. Robert also serves as an independent director at the early-stage cancer immunotherapy company Enara Bio, the Alliance for Regenerative Medicine, and the Healthcare and Pharmaceutical Management Advisory Board of Columbia Business School.</p>		https://www.linkedin.com/in/robert-ang-069746/	rang@vorbio.com
Trending Topic	Rakesh Dixit		Cofounder, President and CSO, Regio Biosciences	Rakesh headshot	Rakesh-Dixit.jpg	Rakesh Shortbio	<p>Rakesh Dixit is a distinguished executive, inventor, and scientist with over 35 years of experience in the biotechnology and pharmaceutical sectors, notably at Merck, Johnson & Johnson, and MedImmune - AstraZeneca. He currently holds prominent positions as President and CSO of Regio Biosciences and Bionavigen Oncology, LLC, and is a Board Member of Regio Biosciences. Dr. Dixit has been globally recognized, receiving the Most Prestigious Award for Long-Standing Contribution to ADCs by World ADC in 2020, and being named one of the 100 Most Inspiring People in the Pharmaceutical Industry by PharmaVOICE in 2015. He has served as Global Vice President of Biologics R&D at MedImmune - AstraZeneca from 2006 to 2019. His expertise spans across developing various biologics and small-molecule biopharmaceuticals, encompassing discovery, preclinical development, safety assessment, and translational sciences. Dr. Dixit is a Board Certified Toxicologist since 1992, trained at esteemed institutions including Case Western Reserve University and the University of Nebraska.<p>		https://www.linkedin.com/in/rakesh-dixit-ph-d-dabt-8979309/	rakesh.dixit@bionavigen.com
Trending Topic	Yvonne (Yi-Yang) Lau		Executive Director, Daiichi Sankyo	Yvonne headshot	Yvonne-Lau_headshot.jpg	Yvonne ShortBio	<p>Yvonne Lau, PhD, is currently an Executive Director and Oncology Portfolio Lead within the Quantitative Clinical Pharmacology Department of the Global Precision Medicine function at Daiichi Sankyo, Inc. Her group provides strategic clinical pharmacology and pharmacometrics support to oncology programs, spanning early to late stages, across different molecule modalities (small molecules, mAbs, ADCs). Before joining Daiichi Sankyo, Yvonne held increasingly responsible roles in the Oncology Clinical Pharmacology departments at Janssen and Novartis. Earlier in her career, she worked in the DMPK and Clinical Pharmacology groups at Amgen and MedImmune, contributing across multiple therapeutic areas. Yvonne earned her Ph.D. in Biopharmaceutical Sciences from the University of California, San Francisco. She has over 17 years of industry experience in the development of small molecules and biologics, along with extensive experience with global regulatory interactions, having contributed to a number of successful filings.</p>		https://www.linkedin.com/in/yvonne-yi-yang-lau-555974a/	ylau@dsi.com
Trending Topic	Ting-Hui Wu	吳庭輝	Senior Medical Director, Mythic therapeutics		Ting-Hui-Wu.jpg	https://docs.google.com/document/d/1i7n8I1CxqnL30hSM_NK2DEUkUiqsrzmK/edit?usp=sharing&ouid=104941311771459350525&rtpof=true&sd=true	<p>Ting-Hui Wu is a Senior Medical Director in Clinical Development at Mythic Therapeutics. He leads the global development of MYTX-011, a novel pH-engineered ADC, and contributes to shaping Mythic’s ADC pipeline. Prior to joining Mythic, he led the development of a first-in-class mRNA epigenomic anticancer therapy at Omega Therapeutics. Prior to joining Omega, he served as an Engagement Manager in the Life Science Practice at McKinsey & Company, supporting biotech and pharmaceutical companies on pipeline/asset strategy, business development, and due diligence. Ting holds an M.D. from the National Taiwan University and completed his internal medicine and medical oncology training at the National Taiwan University Hospital. He also received an M.S. in cancer epidemiology from the Johns Hopkins Bloomberg School of Public Health. </p>		https://www.linkedin.com/in/ting-hui-wu-md-msc-ab535733/	dr.ting.wu@gmail.com
Trending Topic	Yuk-Cheung (Chris) Chan		Senior Scientist, AstraZeneca	https://docs.google.com/document/d/1aRlzULLoCNFtsQzuZBtt3scJwmUGtjpH/edit?usp=sharing&ouid=104941311771459350525&rtpof=true&sd=true	yuk-cheung-chris-chan.jpeg	https://docs.google.com/document/d/1aRlzULLoCNFtsQzuZBtt3scJwmUGtjpH/edit?usp=sharing&ouid=104941311771459350525&rtpof=true&sd=true	<p>Chris Chan was born and raised in Hong Kong. He received PhD in Chemistry under the supervision of Prof. Ying-Yeung Yeung from The Chinese University of Hong Kong in 2019. His graduate research focused on application of non-covalent interaction in organocatalysis. Motivated by the power of small molecule, he joined Prof. Scott Miller’s group as a Postdoctoral Associate in Yale University, where he has developed new peptide catalysis for heterocycle functionalization with high generality. Chris was also a member in Center for Genetically Encoded Materials (NSF Center) for studying beta-amino acid effect in ternary complex stability. He started his industrial career in Eisai, then moved to AstraZeneca in 2024 as Senior Scientist to work on Antibody-Drug-Conjugate (ADC) and other targeted delivery. Chris’s research has been published in J. Am. Chem. Soc., Angew. Chem. Int. Ed., ACS Cent. Sci. and Org. Lett.</p>		https://www.linkedin.com/in/yuk-cheung-chan-7b9630188/	chris.chan@astrazeneca.com
Panel#1 Advanced Bioprocessing	Mark Brader		Fellow, Technical Development, Moderna	Mark headshot and short bio	Mark-Brader.jpg	Mark headshot and short bio	<p>Dr. Mark Brader, PhD, is a Research Fellow and group leader in the Technical Development division at Moderna, responsible for mRNA-lipid nanoparticle characterization and biophysical analysis. He is a formulations and biophysical development scientist with over 20 years’ experience leading technical teams. His work reflects a longstanding curiosity about the molecular pharmaceutics of higher-order structures and the impact of non-covalent phenomena on product quality attributes. He has contributed to elucidating key fundamentals of mRNA-lipid nanoparticles and was part of the team that developed the Moderna Covid-19 vaccine during the pandemic. As part of his leadership role at Moderna, he also serves as People Champion for scientific excellence, engagement, wellness and belonging within Analytical Development. In previous roles within the pharmaceutical biotechnology industry, Dr. Brader has worked extensively on drug product development of insulin analogs, GLP-1 peptides, enzymes, and monoclonal antibodies. On a personal note, Dr. Brader grew up in New Zealand where he conducted his scientific training at Massey University, graduating with a PhD in Chemistry. Prior to starting his industrial career as a Senior Pharmaceutical Scientist at Eli Lilly and Company, he held postdoctoral positions at the University of California at Riverside, Department of Biochemistry and at Rutgers University, Department of Chemistry.</p>		https://www.linkedin.com/in/bioactive/	mark.brader@modernatx.com
Panel#1 Advanced Bioprocessing	Nicole Payton		Director, Drug Product Development, AstraZeneca		nicole-payton.jpeg				https://www.linkedin.com/in/nicole-payton-26934098/	nicole.m.payton@gmail.com
Panel#1 Advanced Bioprocessing	Chih-Chi (Jimmy) Chu	朱治齊	Associate Director, Process & Analytical Sciences, Regeneron		Jimmy_Chu.jpeg				https://www.linkedin.com/in/chih-chi-jimmy-chu-526b0073/	cchujimmy@gmail.com
Panel#1 Advanced Bioprocessing	Samantha Hullah		Head of Process Development / Site Head, FUJIFILM Diosynth Biotechnologies 		Samantha-Hullah.jpeg				https://www.linkedin.com/in/samanthahullah/	samanthahullah@gmail.com
Panel#2 Business Development	Gina Song		Senior Director of Business Development at Schrödinger		gina-song.jpeg	https://docs.google.com/document/d/1iI9fdyAYeXFri1ydfOsELXquecfTsVNKhl1vEHLeAxI/edit	<p>Gina is the Senior Director of Business Development at Schrödinger, bringing over eight years of experience in the biotech and biopharma industry. With a strong track record in both in-licensing and out-licensing deals, Gina has played a pivotal role in advancing strategic partnerships of Schrödinger.</p>  <p>Gina holds a bachelor’s and master’s degree in biology and biochemistry from Tsinghua University as well as an MBA from UC Berkeley. Before transitioning to the biotech sector, Gina spent six years in investment banking. She is passionate about the intersection of business development and healthcare and is dedicated to accelerating the development of new drugs to benefit patients worldwide.</p>		https://www.linkedin.com/in/gesong16/?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=android_app	gina.song@schrodinger.com
Panel#2 Business Development	Po-Jen (Will) Yen	顏伯任	Head of Search, Evaluation & Licensing - Voyager Therapeutics		Po-Jen_Yen.jpg	https://docs.google.com/document/d/1iI9fdyAYeXFri1ydfOsELXquecfTsVNKhl1vEHLeAxI/edit	<p>As a core member of the Corporate and Business Development team at Voyager Therapeutics, Will has led increasingly important business development activities and played significant roles in corporate development to facilitate company growth, driving strategy, competitive intelligence, as well as supporting research and development with both his science and business expertise. Prior to Voyager, Will worked at Biogen Corporate Strategy, where he analyzed neurodegenerative disease space with a comprehensive approach to identify trends and barriers of the field, thereby informing the company's investment opportunities and long-term strategy. A research scientist by training, Will started his career at Agios, after receiving a PhD in Virology at Harvard University, a Master in Biotechnology at University of Pennsylvania, and a Bachelor in Zoology at National Taiwan University.</p>		https://www.linkedin.com/in/willyen/	pojenyen@gmail.com
Panel#2 Business Development	Irene Lau		VP Business Development - Intellia Therapeutics		irene-lau.jpeg	https://docs.google.com/document/d/1iI9fdyAYeXFri1ydfOsELXquecfTsVNKhl1vEHLeAxI/edit?usp=sharing	<p>Irene Lau is the Vice President of Business Development at Intellia Therapeutics, where she leads the development of the Company's cell therapy partnering strategy and drives strategic partnering initiatives to advance its innovative engineered cell therapy platforms. Prior to Intellia, Irene held a leadership role in portfolio strategy at Alnylam Pharmaceuticals, where she spearheaded the development of the company's long-range plan. As part of the business development team at Alnylam, she also played an integral role in major alliances, including an $800M partnership with Regeneron. With over 15 years of experience spanning biotech business development, corporate strategy, and Wall Street equity research, Irene brings a unique blend of strategic acumen and deal-making expertise to drive the growth and success of cutting-edge biotech companies.</p>		https://www.linkedin.com/in/irene-lau-b33b8612/	irenelau08@gmail.com
Panel#2 Business Development	JM Lee		Transactions lead in the Corporate Development/ BD department at Novo Nordisk		jm-lee.jpeg	https://docs.google.com/document/d/1iI9fdyAYeXFri1ydfOsELXquecfTsVNKhl1vEHLeAxI/edit	<p>JM is a transactions lead in the Corporate Development/ BD department at Novo Nordisk, spending most of her time on in-licensing and collaboration negotiations. She is the main business partner to Novo's Bio Innovation Hub, a Boston-based research unit tasked with collaborating with unique platforms to discover novel therapeutics. Prior to Novo Nordisk, JM was a BD lead at Takeda's Center for External Innovation, Sanofi's global transactions, and Bioverativ (spin-out of Biogen acquired by Sanofi). She started her career as a consultant at McKinsey & Co. in the pharmaceuticals & medical products practice after her PhD in Chemistry at MIT. JM holds her Bachelor's in Biochemistry and Mathematics from Bates College.</p>		https://www.linkedin.com/in/jm-lee-02118/	QSJL@novonordisk.com
Panel#3 Translational Science	Yi-Li Min	閔譯立	Associate Director @ Vertex Cell and Genetic Therapies | Gene Editing & Nonclinical Research		Academia_Yi-Li_Min.jpg				https://www.linkedin.com/in/yilimin/
Panel#3 Translational Science	Emily Hsiue	薛涵中	Senior Medical Director, Early Clinical Development, Oncology, AZ	https://drive.google.com/file/d/1lKXOFFtnBGVJoXxFxP5hC5t8NySqmJbv/view?usp=drive_link	emily-hsiue.jpeg	https://docs.google.com/document/d/1piizHYJLk_Et-LplUwTnydeOffwVUSx7n0RQKAq2d9E/edit?usp=sharing	<p>Emily Hsiue is a Senior Medical Director in Early Clinical Development, Oncology at AstraZeneca in Waltham, MA. She is responsible for overseeing the clinical strategy and designing the first-in-human/Phase 1 studies for novel cancer therapeutics. Prior to AstraZeneca, she was a Clinical Program Leader at Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA, leading early immune-oncology drug development programs spanning from small molecules to biologics. Emily completed a Ph.D. under Dr. Bert Vogelstein at Johns Hopkins School of Medicine, where she studied targeting cancer neoantigens using TCR-mimic T-cell engagers. She also holds an M.D. from the National Taiwan University and completed her internal medicine and medical oncology training at the National Taiwan University Hospital.</p>	Lunch	https://www.linkedin.com/in/emily-hsiue-117a32ba/
Panel#3 Translational Science
Panel#3 Translational Science
Panel#3 Translational Science (Back up)	Magaret Wey	魏嘉英	Director of Global Medicines Development, AZ		Margaret_Wey.jpg
Panel#4 Biotech Entrepreneurship	Robert Ang		President and CEO - VOR Bio	Robert_headshot	robert-ang.jpeg	Robert short bio	<p>Robert Ang, MBBS, MBA, is President and CEO at Vor Bio, a publicly-traded company working on next-generation hematopoietic stem cell transplants. Vor uses stem cells, gene editing, and CAR-T technologies with the hope of curing liquid tumors. Vor has raised over $470M in gross proceeds from private and public financing and has translated the science into two clinical programs treating patients with acute myeloid leukemia and myelodysplastic syndrome.</p>  <p>Prior to Vor, Robert had operational experience focused on strategy and business development roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also had biotech venture capital experience at Frazier Healthcare Ventures where he invested in companies such as Incline Therapeutics (now Novartis) and Alnara Pharmaceuticals (now Eli Lilly), and strategy consulting experience at the Boston Consulting Group. His clinical practice centered around soft tissue surgery with an emphasis around solid organ transplants. He received his medical degree at the University of Western Australia and has an MBA with Honors from Columbia Business School. Robert also serves as an independent director at the early-stage cancer immunotherapy company Enara Bio, the Alliance for Regenerative Medicine, and the Healthcare and Pharmaceutical Management Advisory Board of Columbia Business School.</p>		https://www.linkedin.com/in/robert-ang-069746/	rang@vorbio.com
Panel#4 Biotech Entrepreneurship	Daniel Fischer		Co-Founder, President and CEO - TEVARD Biosciences		Daniel-Fischer.jpg		<p>Daniel Fischer co-founded Tevard Biosciences to develop gene therapy approaches to cure Dravet Syndrome — a disease that affects his daughter Natasha — and other rare diseases not amenable to traditional gene therapy approaches. He brings extensive management and entrepreneurial expertise. Daniel has been a management consultant to Fortune 500 companies with several top-tier consultancies, including A.T. Kearney and Arthur D. Little. Daniel worked at the Massachusetts Institute of Technology with industry, academic researchers, and startups in advancing the state-of-the-art in multiple disciplines, including: AI/machine learning, biotechnology, nanotechnology, IoT, and innovation management. Daniel was the founder and CEO of Intellimedix which he co-founded to develop and implement a platform for personalized medicine. In 2000 he co-founded and managed Comerxia, a company that was featured in TIME magazine as the leading solution for international ecommerce.</p>		https://www.linkedin.com/in/daniel-fischer-2b1a363/	dfischer@tevard.com
Panel#4 Biotech Entrepreneurship	Sabrina Yang		Co-Founder and Chief Innovation Officer - Empress Therapeutics		sabrina-yang.jpeg				https://www.linkedin.com/in/sabrina-yang-a0438b53/	syang@flagshippioneering.com
Lunch - Industry	Jason Lu
Lunch - Industry	Wen-Chi Chou	周文奇	Associate Director, Computational Biology in Clinical & Translational Oncology, BMS	https://docs.google.com/document/d/14S-BF8kDm1xhNlZvz5jgBiaciAB91o_QyiPbqj5zPAs/edit?usp=sharing	wen-chi-chou.jpg	https://docs.google.com/document/d/14S-BF8kDm1xhNlZvz5jgBiaciAB91o_QyiPbqj5zPAs/edit?usp=sharing	<p>Wen-Chi Chou, Ph.D., currently the Associate Director of Computational Biology at Bristol-Myers Squibb (BMS), is a distinguished leader in computational biology and bioinformatics, with a career spanning academia and several leading pharmaceutical companies. Starting his industrial career as Team Lead for Data Science & Computational Biology at Obsidian Therapeutics, Wen-Chi has built an impressive trajectory through roles at Takeda and contributions at BMS. He holds a Ph.D. in Bioinformatics from the University of Georgia, a Master's in Cellular and Molecular Biology from Taipei Medical University. He completed postdoctoral research at the Broad Institute and Harvard Medical School. Presently pursuing an MBA at Boston College, he has led teams in clinical development, translational studies, and drug discovery, particularly in oncology, gastrointestinal, and liver diseases. As a seasoned interviewer and hiring manager, Wen-Chi offers profound insights into the hiring process in the competitive industry field and mentors emerging scientists in successfully navigating job interviews. To explore Wen-Chi Chou's professional path and gather insights from his career, visit his LinkedIn profile: www.linkedin.com/in/wenchichou.</p>		https://www.linkedin.com/in/wenchichou/
Lunch - Industry	Star Chen	陳思達
Lunch - Industry	Po-Jen (Will) Yen	顏伯任	Head of Search, Evaluation & Licensing - Voyager Therapeutics		Po-Jen_Yen.jpg	https://docs.google.com/document/d/1iI9fdyAYeXFri1ydfOsELXquecfTsVNKhl1vEHLeAxI/edit	<p>As a core member of the Corporate and Business Development team at Voyager Therapeutics, Will has led increasingly important business development activities and played significant roles in corporate development to facilitate company growth, driving strategy, competitive intelligence, as well as supporting research and development with both his science and business expertise. Prior to Voyager, Will worked at Biogen Corporate Strategy, where he analyzed neurodegenerative disease space with a comprehensive approach to identify trends and barriers of the field, thereby informing the company's investment opportunities and long-term strategy. A research scientist by training, Will started his career at Agios, after receiving a PhD in Virology at Harvard University, a Master in Biotechnology at University of Pennsylvania, and a Bachelor in Zoology at National Taiwan University.</p>		https://www.linkedin.com/in/willyen/
Lunch - Industry	Jessica Huang
Lunch - Industry	Ting-Hui Wu	吳庭輝	Senior Medical Director, Mythic therapeutics		Ting-Hui-Wu.jpg	https://docs.google.com/document/d/1i7n8I1CxqnL30hSM_NK2DEUkUiqsrzmK/edit?usp=sharing&ouid=104941311771459350525&rtpof=true&sd=true	<p>Ting-Hui Wu is a Senior Medical Director in Clinical Development at Mythic Therapeutics. He leads the global development of MYTX-011, a novel pH-engineered ADC, and contributes to shaping Mythic’s ADC pipeline. Prior to joining Mythic, he led the development of a first-in-class mRNA epigenomic anticancer therapy at Omega Therapeutics. Prior to joining Omega, he served as an Engagement Manager in the Life Science Practice at McKinsey & Company, supporting biotech and pharmaceutical companies on pipeline/asset strategy, business development, and due diligence. Ting holds an M.D. from the National Taiwan University and completed his internal medicine and medical oncology training at the National Taiwan University Hospital. He also received an M.S. in cancer epidemiology from the Johns Hopkins Bloomberg School of Public Health. </p>		https://www.linkedin.com/in/ting-hui-wu-md-msc-ab535733/
Lunch - Industry	Hsiao-Ling Hung	洪筱玲	President, Taiwanese American Association of Biotechnology (TAAB)		Hsiao-Ling_Hung.jpeg	https://docs.google.com/document/d/10XQ4DE4CSOad9bYgSBMS-EiiFq4VNKLLWPLu49zzzvs/edit?usp=drive_link	<p>Hsiao-Ling is currently an independent drug development consultant.</p> <p>Prior to semi-retirement at the end of 2022, Hsiao-Ling was the Senior VP, Head of Regulatory Affairs and Quality Assurance at Ambrx, a public clinical-stage biotech company that focuses on developing Engineered Precision Biologics (Ambrx.com, NASDAQ: AMAM). Ambrx was acquired by Johnson & Johnson in January 2024.</p> <p>Hsiao-Ling was previously Senior Director in Global Regulatory Sciences at Bristol-Myers Squibb, leading regulatory strategy and managing regulatory staff for the Opdivo (anti-PD1) and Yervoy (anti-CTLA4) lung cancer and gastric cancer portfolios.</p> <p>Prior to BMS, Hsiao-Ling spent 10 years at Janssen Pharmaceutical Companies of Johnson & Johnson, first as an Asia Pacific Latin America Regulatory Lead, then a North America Regulatory Lead in Oncology. She led the regulatory strategy and execution for the Balversa (erdafitinib, an FGFR inhibitor) program from first-in-human study to NDA approval.</p> <p>Prior to a career in regulatory affairs, Hsiao-Ling was a scientist for over 20 years. At Genaera Corporation, a biopharmaceutical company, she led the discovery and preclinical research programs of compounds across multiple therapeutic areas, including oncology, ophthalmology, metabolic disease and respiratory disease.</p> <p>Hsiao-Ling received a B.S. in Medical Technology from the National Taiwan University and a Ph.D. in Pathology and Molecular Biology from the University of Pennsylvania.</p>		https://www.linkedin.com/in/hsiao-ling-hung-phd-rac-7771113/
Lunch - Industry	Emily Hsiue	薛涵中	Senior Medical Director, Early Clinical Development, Oncology, AZ	https://drive.google.com/file/d/1lKXOFFtnBGVJoXxFxP5hC5t8NySqmJbv/view?usp=drive_link	emily-hsiue.jpeg	https://docs.google.com/document/d/1piizHYJLk_Et-LplUwTnydeOffwVUSx7n0RQKAq2d9E/edit?usp=sharing	<p>Emily Hsiue is a Senior Medical Director in Early Clinical Development, Oncology at AstraZeneca in Waltham, MA. She is responsible for overseeing the clinical strategy and designing the first-in-human/Phase 1 studies for novel cancer therapeutics. Prior to AstraZeneca, she was a Clinical Program Leader at Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA, leading early immune-oncology drug development programs spanning from small molecules to biologics. Emily completed a Ph.D. under Dr. Bert Vogelstein at Johns Hopkins School of Medicine, where she studied targeting cancer neoantigens using TCR-mimic T-cell engagers. She also holds an M.D. from the National Taiwan University and completed her internal medicine and medical oncology training at the National Taiwan University Hospital.</p>	Lunch	https://www.linkedin.com/in/emily-hsiue-117a32ba/
Lunch - Industry	Chris Fang	方威凱
Lunch - Industry
Lunch - Academic	Hsiao-Ying Monica Wey	魏曉英			Academia_Wey.jpg				https://weylab.martinos.org	hsiaoying.wey@mgh.harvard.edu
Lunch - Academic	Yi-Yun Ho	何逸雲	MIT postdoc fellow	https://drive.google.com/drive/u/0/folders/1GrEWCBBhZ0IXpiMrx3qKJ-txla-ht25T	Yi-Yun_Ho.jpg	https://docs.google.com/document/d/1IIPLa2wzFxwJCIW_wqx6Hf6kyKZqRCqBVPF6yBlRE6A/edit	<p>Dr. Yi-Yun Ho received her BS and MS in physics from National Taiwan University. She then transitioned to study biology system and completed a Master of Engineering in biomedical engineering and a PHD in neuroscience both at Cornell University. In her PhD, she identified a key neuron population in initiating proactive threat avoidance, suggesting a potential target for depression treatments. She then did her postdoc training at McGovern Institute for Brain Research at MIT with Dr. Guoping Feng, where she applied her strength in quantitative models and imaging analysis to study the mechanism and pinpoint treatment targets of schizophrenia and autism. Besides academic research, she served as a co-chair at Boston Taiwnese Biotechnology Association. She is now an account executive at Sino Biological.</p>		https://www.linkedin.com/in/y-yun-ho-476b995b?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_app	yi.yun.a.ho@gmail.com
Lunch - Academic	Meng-Ju Wu	吳孟儒	Assistant Professor at the University of Massachusetts Chan Medical School	https://drive.google.com/file/d/1_IuBTt33xOOdwG0peNkmIifvZrWXQSZs/view?usp=drive_link	Meng-Ju_Wu.jpg	https://docs.google.com/document/d/1awxtOMqO9q_ew-EM0oGOBjmVPzYoPXrX/edit?usp=drive_link&ouid=101153837354658925534&rtpof=true&sd=true	<p>Dr. Meng-Ju Wu completed his B.S. and M.S. in Life Science and Oral Biology at National Yang-Ming University. He earned his Ph.D. at Purdue University, focusing on epigenetic mechanisms in stem cells. He is currently an instructor at Massachusetts General Hospital, Department of Medicine, Harvard Medical School, where he researches IDH1 mutant intrahepatic cholangiocarcinoma. His work has revealed key insights into immune evasion and the effects of IDH inhibition. In October 2024, he will start his independent lab as an Assistant Professor at the University of Massachusetts Chan Medical School.</p>		https://www.linkedin.com/in/meng-ju-wu/	itsacurse@gmail.com	8HF715
Lunch - Academic	Ming-Ru Wu	吳名儒			Academia_Ming-Ru_Wu.jpg					ming-ru_wu@dfci.harvard.edu
Lunch - Academic	Mong-Hsun Tsai	蔡孟勳	Professor and Director, TECO Boston/NTU IOB			https://docs.google.com/document/d/1OWtmtByDGEde9r9MjnfBPZeM94LLS4t2RZsavtpVri0/edit	<p>Professor Mong-Hsun Tsai received his Bachelor's and Master's degrees from National Taiwan University and Tsinghua University, respectively. He then earned his Ph.D. from the Institute of Public Health in National Yang-Ming University. Dr. Tsai conducted postdoctoral research at the National Institutes of Health (NIH), where he focused on microarray fabrication and big data analysis in the Microarray Core Facility at the National Cancer Institute (NCI). In 2006, Dr. Tsai joined the Institute of Biotechnology at National Taiwan University as an assistant professor. He was promoted to full professor in 2017 and became the director of the Institute of Biotechnology in 2021.</p> <p>Professor Tsai's primary research interests focus on utilizing high-throughput platforms such as microarrays and next-generation sequencing (NGS) to understand the genomic variations in cancer cells and their role in the processes of cellular carcinogenesis and malignancy progression. His research has made significant contributions to the understanding and treatment of cancer. In recent years, his laboratory has further extended its focus to the sequencing and analysis of the gut microbiota, exploring the relevance and importance of the gut microbiome in human environmental health. In 2022, Professor Tsai was transferred to Boston as the director of the Science and Technology Division, dedicating himself to the field of science and technology diplomacy.</p>
Lunch - Academic	Yen-Cheng Chen	陳晏誠	Senior Scientist, ChemBio (Discovery Chemistry), Merck	https://drive.google.com/file/d/1x632adqSqhv5sZhzx1EAlXvdhvIkP3TM/view?usp=drive_link	yeh-cheng-chen.jpg	https://docs.google.com/document/d/1ZV8WlbxkgveT_TvYlbLv9riAwHPGyH_2/edit?usp=drive_link&ouid=101153837354658925534&rtpof=true&sd=true	<p>Yen-Cheng is a senior scientist at Merck. He got his chemistry PhD from Georgia Tech, and his postdoctoral research focused on membrane protein distribution on single viruses (i.e., HIV-1) with advanced fluorescence microscopy at Emory University. Last year, he started working in Merck to build advanced fluorescence microscopy capability and collaborate with multiple Merck’s postdocs in disease areas. Besides work, he enjoys traveling and movies. He has volunteered at BTBA as a mentor, organized job searching panel discussion and trending topic in the BTBA annual meeting.</p>		https://www.linkedin.com/in/yen-cheng-chen/
Breakfast 	Hsiao-Ling Hung	洪筱玲	President, Taiwanese American Association of Biotechnology (TAAB)		Hsiao-Ling_Hung.jpeg	https://docs.google.com/document/d/10XQ4DE4CSOad9bYgSBMS-EiiFq4VNKLLWPLu49zzzvs/edit?usp=drive_link	<p>Hsiao-Ling is currently an independent drug development consultant.</p> <p>Prior to semi-retirement at the end of 2022, Hsiao-Ling was the Senior VP, Head of Regulatory Affairs and Quality Assurance at Ambrx, a public clinical-stage biotech company that focuses on developing Engineered Precision Biologics (Ambrx.com, NASDAQ: AMAM). Ambrx was acquired by Johnson & Johnson in January 2024.</p> <p>Hsiao-Ling was previously Senior Director in Global Regulatory Sciences at Bristol-Myers Squibb, leading regulatory strategy and managing regulatory staff for the Opdivo (anti-PD1) and Yervoy (anti-CTLA4) lung cancer and gastric cancer portfolios.</p> <p>Prior to BMS, Hsiao-Ling spent 10 years at Janssen Pharmaceutical Companies of Johnson & Johnson, first as an Asia Pacific Latin America Regulatory Lead, then a North America Regulatory Lead in Oncology. She led the regulatory strategy and execution for the Balversa (erdafitinib, an FGFR inhibitor) program from first-in-human study to NDA approval.</p> <p>Prior to a career in regulatory affairs, Hsiao-Ling was a scientist for over 20 years. At Genaera Corporation, a biopharmaceutical company, she led the discovery and preclinical research programs of compounds across multiple therapeutic areas, including oncology, ophthalmology, metabolic disease and respiratory disease.</p> <p>Hsiao-Ling received a B.S. in Medical Technology from the National Taiwan University and a Ph.D. in Pathology and Molecular Biology from the University of Pennsylvania.</p>		https://www.linkedin.com/in/hsiao-ling-hung-phd-rac-7771113/		yes
Breakfast	Maurice Shen	沈彥甫	Account Manager, Schrödinger 		Maurice-Shen.jpeg				https://www.linkedin.com/in/maurice-shen-ph-d-40a86121/	Mauriceyfshen@gmail.com
Breakfast	Anthony Wang		Analyst, ClearView Healthcare Partners		Anthony-Wang.jpeg				https://www.linkedin.com/in/wanganthonyas/
Breakfast	Rose Lee		Quality Assurance/Regulatory Affairs Manager, Pillar Biosciences Incorporate		Rose-Lee.jpeg				https://www.linkedin.com/in/ming-jeng-lee-rose/
Breakfast	Robert Morfino		Senior Director Business Development, Ginkgo Bioworks, Inc.		Robert-Morfino.jpeg				https://www.linkedin.com/in/robertocristophermorfino/	rmorfino@ginkgobioworks.com
Breakfast	Kate Worthington		SVP Medical Affairs: pre-commercialization, Next Phase Biotech		Kate-Worthington.jpeg				https://www.linkedin.com/in/kate-worthington/	kate@nextphasebiotech.com
Breakfast	June Lin	林靜君	Executive Medical Director, US & Global Medical Affairs, Regeneron		June-Lin.jpeg				https://www.linkedin.com/in/junelin20202023	junelin2011@gmail.com	yes
Breakfast	Hee June Choi		Senior Clinical Scientist, Merck		Hee-June-Choi.jpeg				https://www.linkedin.com/in/heejunechoi/
Breakfast
Breakfast											`;

const tsv_array = tsv_str
	.split('\n')
	.map(el => el.split('\t'))
	.filter(el => el[1])
	.map(el => {
		return {
			'name': el[1].trim() || null,
			'nameCh': el[2] || null,
			'affiliations': el[3] ? el[3].split(';') : [],
			'imgFileName': el[5] || 'placeholder.jpg',
			'links': el[9] ? el[9].split(';') : [],
			'description': el[7] || ''
		};
	});

const tsv_dict = {};

tsv_array.forEach(el => {
	el.name.trim() in Object.keys(tsv_dict)
		? false
		:  tsv_dict[el.name.trim()] = el;
});

export const speakersObj = tsv_dict;
